RxDoctor Payments Data

Katherine Edelen, PA

Medical · Thomasville, GANPI 1205334737

Payments from drug & device makers

$560in general payments, 2019–2025

Across 21 payments — averaging $26.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$340
  • Sunovion Pharmaceuticals Inc.$52
  • Alkermes, Inc.$51
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$29
  • AbbVie$26
  • Lundbeck LLC$22
  • plus $39 from 2 others

What the payments were for

  • Food & beverage$560100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$560 in reported general payments places this provider in the 45th percentile of 950 medical providers in Georgia.

See all medical providers in Georgia

Medicare billing

Part B allowed, 2024
$9,310
Medicare patients
44
Services billed
185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine27$183,872
IngrezzaValbenazine Tosylate18$144,405
Invega SustennaPaliperidone Palmitate46$143,535
AristadaAripiprazole Lauroxil44$139,358
Invega TrinzaPaliperidone Palmitate12$107,466
VraylarCariprazine Hcl40$57,470
Risperdal ConstaRisperidone Microspheres34$56,197
Abilify MaintenaAripiprazole20$51,401
RexultiBrexpiprazole35$35,211
Lurasidone Hcl37$14,944
Aripiprazole22$5,460
Atomoxetine Hcl51$2,917
Benztropine Mesylate256$2,854
Trazodone Hcl229$2,572
Divalproex Sodium ErDivalproex Sodium107$1,938

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta$340$307,19892 claims
Alkermes, Inc.Aristada$51$139,35844 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$19$86,61255 claims
AbbVieVraylar$26$57,47040 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 950 medical providers in Georgia.

Other medical in Thomasville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →